Read on Twitter
This morning feels bittersweet.
5 years ago, I first heard from the office of the late @RepCummings after I wrote an oped on the high cost of drugs.
Today and tomorrow's drug pricing hearings are a testament to him and his tireless work to curb the high cost of meds.
5 years ago, I first heard from the office of the late @RepCummings after I wrote an oped on the high cost of drugs.
Today and tomorrow's drug pricing hearings are a testament to him and his tireless work to curb the high cost of meds.
That op-ed, in CNN, elevated the drug patent problem as a key driver to the drug pricing crisis: https://www.cnn.com/2015/06/02/opinions/radhakrishnan-drug-prices/index.html
Then, two years ago, @imakglobal put out the report series Overpatented, Overpriced that went viral: https://www.i-mak.org/overpatented/
Then, two years ago, @imakglobal put out the report series Overpatented, Overpriced that went viral: https://www.i-mak.org/overpatented/
Since then, alongside our amazing partners – @ProfRobnFeldman, @akesselheim, and so many others in the #access2meds movement — we have collectively put the drug patent problem on the map.
Since then, we have seen bipartisan action (from leaders like @JohnCornyn and @SenBlumenthal) on manipulation of the patent system and important challenges to patent thickets.
It's a start, and we need a whole lot more from Congress.
It's a start, and we need a whole lot more from Congress.
It has taken 5 years in the U.S., but we are finally seeing action to investigate the system-wide failure to curb abusive monopolies.
Today's report provides a scathing indictment on high drug costs and places patent abuse squarely at the heart of it.
https://oversight.house.gov/sites/democrats.oversight.house.gov/files/Celgene%20BMS%20Staff%20Report%2009-30-2020.pdf
Today's report provides a scathing indictment on high drug costs and places patent abuse squarely at the heart of it.
https://oversight.house.gov/sites/democrats.oversight.house.gov/files/Celgene%20BMS%20Staff%20Report%2009-30-2020.pdf
This is an issue that hurts ALL Americans - and by extension, people around the world.
We're not going to solve the drug pricing problem until we solve the drug patent problem.
We're not going to solve the drug pricing problem until we solve the drug patent problem.
